Navigation Links
Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
Date:12/20/2007

Summary: Genmab's Partner, Roche has Initiated a Phase II study of R1507

for the Treatment of Sarcoma

COPENHAGEN, Denmark, December 20 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner, Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma. The R1507 antibody was created by Genmab under the company's agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of USD 500,000.

"R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that R1507 may offer an additional treatment option to sarcoma patients."

About Sarcoma

Sarcoma is a cancer of the connective tissue including muscle, bone, fat, nerve, cartilage, blood vessel and deep skin tissue. Due to the wide variety of types of sarcoma, the disease is often difficult to detect, is often misdiagnosed and is complex to treat. Sarcoma is a rare type of cancer with US incidence of approximately 9,000 to 11,000 new cases per year. Of these approximately 8,000 are cases of soft tissue sarcoma and 2,000 are sarcoma of the bone.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)...  Neogen Corporation (NASDAQ: NEOG ) announced ... ended May 31, increased 19% from the previous year ... to the prior year,s $27,190,000. Adjusted for a 3-for-2 ... in the current year were $0.76, compared to $0.75 ... the 2014 fiscal year established new all-time highs for ...
(Date:7/22/2014)... en SHENZHEN, China , 22 ... (BGI Tech), een dochtermaatschappij van BGI, ,s wereld grootste ... introductie aan van een nieuwe service ten behoeve van ... geavanceerde platform van Complete Genomics. In ... de sector in hoog aanzien staat vanwege de in ...
(Date:7/22/2014)... 2014 In chemical and petrochemical ... common sight. The rapid rise of TDL analyzers ... established as a core gas measurement technology, and ... them the gas analyzer technology of choice for ... in some processes have limited their application range. ...
(Date:7/22/2014)... July 22, 2014 Quorum Review IRB, the ... for large clinical trials called Quick Step™ . The ... to address the research industry’s need for seamless study start-up ... is available for studies planning 50 or more North American ... planned North American site count of 80 or more. Qualifying ...
Breaking Biology Technology:Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3
... 13 leading industry speakers will present at CBI,s 2nd ... on November 14-15, 2011 in Philadelphia. Nearly 100 TMF professionals ... shift taking place in the clinical trials -- moving from ... the heart of a clinical trial, the TMF is re-examined ...
... SEATTLE, Oct. 26, 2011 Immune Design Corp. ... vaccines and immunotherapies for infectious disease, cancer and ... an early-stage research collaboration with Sanofi-Aventis to investigate ... technology, a toll–like receptor 4 (TLR-4) agonist, in ...
... from this smorgasbord of recent salmonella outbreaks in the ... in 2011 alone, and the list goes on, according ... But perhaps not for long, thanks to a promising ... salmonella bacteria before contaminated food or animals reach the ...
Cached Biology Technology:
(Date:7/22/2014)... that feature natural habitats and trees and not just ... according to a University of Colorado Boulder study. , ... also provide stress-reducing benefits for youth, according to a ... The study is one of the first of ... access to green settings and stress. , "Many schools ...
(Date:7/22/2014)... prevent their daughters from breeding, and kill their grandchildren ... desert creatures which live in groups with a dominant ... alpha female can flourish when it maintains the sole right ... life, also found in many animals such as ants and ... Dominant meerkats control breeding within their group through violence, by ...
(Date:7/22/2014)... the genus of planthopper known as Conosimus, which now ... discovered in the southern part of the Iberian Peninsula ... it appears in the open-access Journal of Insect ... species, Conosimus baenai , has been named after ... the taxonomy of Iberian Hemiptera. , Conosimus baenai ...
Breaking Biology News(10 mins):Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3
... , This release is available in French ... researchers have discovered a novel molecular mechanism that prevents cancer. ... Molecular Cell , scientists from the Universit de Montral and ... SOCS1 molecule prevents the cancer-causing activity of cytokines, hormones that ...
... amount of weight by eating less and exercising more improved ... of Medicine in St. Louis. The results of this ... the Journal of the American College of Cardiology , ... measures of heart and vascular health. The improvements seen in ...
... from 190 nations are gathered at the two-week ... about 150 distinguished guests attended an ESA-hosted side ... Essential Climate Variables,. During the event, speakers ... observation satellites play in providing systematic global climate ...
Cached Biology News:Scientists identify natural anti-cancer defenses 2Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3Space agencies join forces to systematically observe climate variables 2Space agencies join forces to systematically observe climate variables 3
... Recognizes Nabeta2. The epitope ... present in any other known ... expected to work on human ... highly conserved (17/19 residues). Reactivity ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
... for DNA isolation. Designed to ... 96 well plate adapters from Mo ... entire plate length (max capacity is ... used for soil, microorganisms, animal tissue, ...
Biology Products: